Targeting Prohibitins to Inhibit Melanoma Growth and Overcome Resistance to Targeted Therapies

Despite important advances in the treatment of metastatic melanoma with the development of MAPK-targeted agents and immune checkpoint inhibitors, the majority of patients either do not respond to therapies or develop acquired resistance. Furthermore, there is no effective targeted therapy currently...

Descripción completa

Detalles Bibliográficos
Autores principales: Najem, Ahmad, Krayem, Mohammad, Sabbah, Serena, Pesetti, Matilde, Journe, Fabrice, Awada, Ahmad, Désaubry, Laurent, Ghanem, Ghanem E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10378173/
https://www.ncbi.nlm.nih.gov/pubmed/37508519
http://dx.doi.org/10.3390/cells12141855

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10378173/
https://www.ncbi.nlm.nih.gov/pubmed/37508519
http://dx.doi.org/10.3390/cells12141855

Ejemplares similares